Annual CFO
-$366.76 M
-$29.25 M-8.67%
December 31, 2023
Summary
- As of February 12, 2025, IBRX annual cash flow from operations is -$366.76 million, with the most recent change of -$29.25 million (-8.67%) on December 31, 2023.
- During the last 3 years, IBRX annual CFO has fallen by -$195.03 million (-113.57%).
- IBRX annual CFO is now -141.11% below its all-time high of -$152.11 million, reached on December 31, 2019.
Performance
IBRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$98.76 M
+$1.58 M+1.58%
September 30, 2024
Summary
- As of February 12, 2025, IBRX quarterly cash flow from operations is -$98.76 million, with the most recent change of +$1.58 million (+1.58%) on September 30, 2024.
- Over the past year, IBRX quarterly CFO has increased by +$1.58 million (+1.58%).
- IBRX quarterly CFO is now -217.49% below its all-time high of -$31.11 million, reached on March 31, 2020.
Performance
IBRX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$421.36 M
-$11.36 M-2.77%
September 30, 2024
Summary
- As of February 12, 2025, IBRX TTM cash flow from operations is -$421.36 million, with the most recent change of -$11.36 million (-2.77%) on September 30, 2024.
- Over the past year, IBRX TTM CFO has dropped by -$11.36 million (-2.77%).
- IBRX TTM CFO is now -1254.56% below its all-time high of -$31.11 million, reached on March 31, 2020.
Performance
IBRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
IBRX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -8.7% | +1.6% | -2.8% |
| 3 y3 years | -113.6% | -23.8% | -25.6% |
| 5 y5 years | -141.1% | -23.8% | -25.6% |
IBRX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -33.6% | at low | -37.9% | +14.3% | -53.5% | at low |
| 5 y | 5-year | -141.1% | at low | -217.5% | +14.3% | -1254.6% | at low |
| alltime | all time | -141.1% | at low | -217.5% | +14.3% | -1254.6% | at low |
ImmunityBio Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$98.76 M(-1.6%) | -$421.36 M(+2.8%) |
| Jun 2024 | - | -$100.35 M(-6.2%) | -$410.00 M(+5.3%) |
| Mar 2024 | - | -$106.98 M(-7.2%) | -$389.43 M(+6.2%) |
| Dec 2023 | -$366.76 M(+8.7%) | -$115.27 M(+31.9%) | -$366.76 M(+7.2%) |
| Sep 2023 | - | -$87.40 M(+9.6%) | -$342.21 M(+2.0%) |
| Jun 2023 | - | -$79.77 M(-5.4%) | -$335.41 M(-3.3%) |
| Mar 2023 | - | -$84.31 M(-7.1%) | -$346.89 M(+2.8%) |
| Dec 2022 | -$337.51 M | -$90.73 M(+12.6%) | -$337.51 M(+6.0%) |
| Sep 2022 | - | -$80.60 M(-11.7%) | -$318.42 M(+2.5%) |
| Jun 2022 | - | -$91.25 M(+21.8%) | -$310.54 M(+7.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$74.93 M(+4.6%) | -$288.88 M(+5.3%) |
| Dec 2021 | -$274.42 M(+59.8%) | -$71.64 M(-1.5%) | -$274.42 M(+5.4%) |
| Sep 2021 | - | -$72.72 M(+4.5%) | -$260.38 M(+15.9%) |
| Jun 2021 | - | -$69.59 M(+15.1%) | -$224.66 M(+11.7%) |
| Mar 2021 | - | -$60.47 M(+5.0%) | -$201.09 M(+17.1%) |
| Dec 2020 | -$171.72 M(+12.9%) | -$57.60 M(+55.7%) | -$171.72 M(+50.5%) |
| Sep 2020 | - | -$36.99 M(-19.6%) | -$114.12 M(+48.0%) |
| Jun 2020 | - | -$46.02 M(+47.9%) | -$77.13 M(+147.9%) |
| Mar 2020 | - | -$31.11 M | -$31.11 M |
| Dec 2019 | -$152.11 M | - | - |
FAQ
- What is ImmunityBio annual cash flow from operations?
- What is the all time high annual CFO for ImmunityBio?
- What is ImmunityBio annual CFO year-on-year change?
- What is ImmunityBio quarterly cash flow from operations?
- What is the all time high quarterly CFO for ImmunityBio?
- What is ImmunityBio quarterly CFO year-on-year change?
- What is ImmunityBio TTM cash flow from operations?
- What is the all time high TTM CFO for ImmunityBio?
- What is ImmunityBio TTM CFO year-on-year change?
What is ImmunityBio annual cash flow from operations?
The current annual CFO of IBRX is -$366.76 M
What is the all time high annual CFO for ImmunityBio?
ImmunityBio all-time high annual cash flow from operations is -$152.11 M
What is ImmunityBio annual CFO year-on-year change?
Over the past year, IBRX annual cash flow from operations has changed by -$29.25 M (-8.67%)
What is ImmunityBio quarterly cash flow from operations?
The current quarterly CFO of IBRX is -$98.76 M
What is the all time high quarterly CFO for ImmunityBio?
ImmunityBio all-time high quarterly cash flow from operations is -$31.11 M
What is ImmunityBio quarterly CFO year-on-year change?
Over the past year, IBRX quarterly cash flow from operations has changed by +$1.58 M (+1.58%)
What is ImmunityBio TTM cash flow from operations?
The current TTM CFO of IBRX is -$421.36 M
What is the all time high TTM CFO for ImmunityBio?
ImmunityBio all-time high TTM cash flow from operations is -$31.11 M
What is ImmunityBio TTM CFO year-on-year change?
Over the past year, IBRX TTM cash flow from operations has changed by -$11.36 M (-2.77%)